Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020065583 - BALIPODECT FOR TREATING OR PREVENTING AUTISM SPECTRUM DISORDERS

Publication Number WO/2020/065583
Publication Date 02.04.2020
International Application No. PCT/IB2019/058187
International Filing Date 26.09.2019
IPC
A61K 31/501 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
50Pyridazines; Hydrogenated pyridazines
501not condensed and containing further heterocyclic rings
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/18 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
CPC
A61K 31/501
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
50Pyridazines; Hydrogenated pyridazines
501not condensed and containing further heterocyclic rings
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Applicants
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED [JP]/[JP]
Inventors
  • MAKHIJA, Mahindra
Priority Data
62/737,98528.09.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BALIPODECT FOR TREATING OR PREVENTING AUTISM SPECTRUM DISORDERS
(FR) BALIPODECT POUR TRAITER OU PRÉVENIR DES TROUBLES DU SPECTRE AUTISTIQUE
Abstract
(EN)
The invention is the use of a PDE10A inhibitor to treat or prevent autism spectrum disorders. More particularly, a method of treating or preventing an autism spectrum disorder selected from the group consisting of autistic disorder, CDKL5 deficiency disorder, childhood disintegrative disorder, Rett syndrome, Fragile X syndrome, Kleefstra syndrome, Pitt Hopkins syndrome, Angelman syndrome, Kabuki syndrome, Asperger's syndrome, Heller's syndrome and Pervasive Developmental Disorder, comprising administering an effective amount of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one or a salt thereof to a mammal. Additionally, a medicament for the treatment or prevention of autism spectrum disorders, and the use of a PDE10A inhibitor in the manufacture of a medicament for the treatment or prevention of autism spectrum disorders.
(FR)
L'invention concerne l'utilisation d'un inhibiteur de PDE10A pour traiter ou prévenir des troubles du spectre autistique. Plus spécifiquement, l'invention concerne un procédé de traitement ou de prévention d'un trouble du spectre autistique choisi dans le groupe constitué par le trouble autistique, le trouble CDKL5, le trouble désintégratif de l'enfance, le syndrome de Rett, le syndrome de L'X Fragile, le syndrome de Kleefstra, le syndrome de Pitt Hopkins, le syndrome d'Angelman, le syndrome de Kabuki, le syndrome d'Asperger, le syndrome de Heller et le trouble envahissant du développement, comprenant l'administration d'une quantité efficace de 1-[2-fluoro-4-(1H-pyrazol-1-yl) phényl]-5-méthoxy-3-(1-phényl-1 H-pyrazol-5-yl) pyridazin-4(1H)-un ou un sel de celui-ci à un mammifère. De plus, l'invention concerne un médicament pour le traitement ou la prévention de troubles du spectre autistique, et l'utilisation d'un inhibiteur de PDE10A dans la fabrication d'un médicament pour le traitement ou la prévention de troubles du spectre autistique.
Latest bibliographic data on file with the International Bureau